Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications.

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Psoriatic arthritis (PsA) is a systemic immune-mediated disease.
• PsA independently elevates the risk of major adverse cardiovascular events (MACE).
• Cardiovascular risk in PsA is often underestimated in clinical practice.

Purpose of the Study:

• To review the epidemiology and pathophysiology linking PsA and cardiovascular risk.
• To provide a framework for managing cardiovascular risk in PsA patients.
• To highlight the impact of inflammation and treatment on cardiovascular outcomes.

Main Methods:

• Narrative review of recent scientific data.
• Synthesis of information on PsA, inflammation, and cardiovascular disease.
• Analysis of the effects of PsA treatments on cardiovascular risk.

Main Results:

• Chronic inflammation in PsA drives metabolic abnormalities and accelerates atherosclerosis.
• Tumor necrosis factor-α (TNF-α) inhibitors may reduce cardiovascular risk.
• Janus kinase (JAK) inhibitors require careful consideration due to potential side effects.

Conclusions:

• A multidisciplinary approach is essential for managing cardiovascular risk in PsA.
• Strict control of both inflammation and traditional risk factors is necessary.
• Reducing the burden of MACE in PsA requires integrated patient management.